Company Information
USD
2.88
- (-%)
NASDAQ:LIXT, LIXTE BIOTECHNOLOGY HOLDINGS INC
Industry: Biotechnology
End of Day: 2 May 2024 GMT-4
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.
Address
680 East Colorado Boulevard
Suite 180
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Dr. John S. Kovach
Chairman of the Board/Chief Scientific Officer/Director/Founder
Mr. Bastiaan van der Baan
Director/President/Vice Chairman of the Board
Mr. Robert Neal Weingarten
CFO/Vice President
Dr. Yun Yen, M.D.
Director
Dr. Stephen J. Forman
Director
Mr. Eric J. Forman, J.D.
COO/Vice President
Dr. James S. Miser, M.D.
Chief Medical Officer
Ms. Regina Brown
Director
Dr. Rene Bernards
Director
Ownership
Institution Holdings
HighTower Advisors, LLC
99,432 (4.421%)
Fidelity Management & Research Company LLC
9,998 (0.445%)
Morgan Stanley - Brokerage Accounts
7,106 (0.316%)
FNY Investment Advisers, LLC
5,500 (0.245%)
Tower Research Capital LLC
2,239 (0.100%)
State Street Global Advisors
435 (0.019%)
Northern Trust Asset Management
215 (0.010%)
Northern Trust Investments Inc
215 (0.010%)
Wells Fargo & Co
9 (0.000%)
UBS Group AG
3 (0.000%)
Funds Holdings
SSgA U.S. Total Market Index Fund
55 (0.002%)
Make Smart Investment Choices